Overview

A Six Week, Double-Blind Randomized, Efficacy and Safety, Sleep Lab Trial With Esmirtazapine (Org 50081) (P05707)

Status:
Completed
Trial end date:
2008-02-13
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to investigate the efficacy, safety and tolerability of esmirtazapine (Org 50081) compared to placebo in patients with chronic primary insomnia.
Phase:
Phase 3
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Collaborator:
Parexel
Treatments:
Mirtazapine